



Greenwich Academic Literature Archive (GALA)
– the University of Greenwich open access repository
<http://gala.gre.ac.uk>

Citation for published version:

Frempong, Kwadwo K., Walker, Martin, Cheke, Robert, Tetevi, Edward J., Gyan, Ernest T., Owusu, Ebenezer O., Wilson, Michael D., Boakye, Daniel A., Taylor, Mark J., Biritwum, Nana-Kwadwo, Osei-Atweneboana, Mike and Basanez, Maria-Gloria (2016) Does increasing treatment frequency address sub-optimal responses to ivermectin for the control and elimination of river blindness? *Clinical Infectious Diseases* (Advance Access). ISSN 1058-4838 (Print), 1537-6591 (Online) (doi:10.1093/cid/ciw144)

Publisher's version available at:

<http://dx.doi.org/10.1093/cid/ciw144>

Please note that where the full text version provided on GALA is not the final published version, the version made available will be the most up-to-date full-text (post-print) version as provided by the author(s). Where possible, or if citing, it is recommended that the publisher's (definitive) version be consulted to ensure any subsequent changes to the text are noted.

Citation for this version held on GALA:

Frempong, Kwadwo K., Walker, Martin, Cheke, Robert, Tetevi, Edward J., Gyan, Ernest T., Owusu, Ebenezer O., Wilson, Michael D., Boakye, Daniel A., Taylor, Mark J., Biritwum, Nana-Kwadwo, Osei-Atweneboana, Mike and Basanez, Maria-Gloria (2016) Does increasing treatment frequency address sub-optimal responses to ivermectin for the control and elimination of river blindness?. London: Greenwich Academic Literature Archive.
Available at: <http://gala.gre.ac.uk/14820/>

Contact: gala@gre.ac.uk

Does Increasing Treatment Frequency Address Sub-optimal Responses to Ivermectin for the Control and Elimination of River Blindness?

Kwadwo K. Frempong^{1,†}, Martin Walker^{2,†}, Robert A. Cheke^{2,3}, Edward Jenner Tettevi⁴, Ernest Tawiah Gyan⁴, Ebenezer O. Owusu⁵, Michael D. Wilson¹, Daniel A. Boakye¹, Mark J. Taylor⁶, Nana-Kwadwo Biritwum⁷, Mike Osei-Atweneboana⁴, María-Gloria Basáñez²

¹Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana

²London Centre for Neglected Tropical Disease Research (LCNTDR), Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, UK

³Natural Resources Institute, University of Greenwich at Medway, Chatham Maritime, UK

⁴Council for Scientific and Industrial Research-Water Research Institute, Accra, Ghana

⁵Department of Animal Biology & Conservation Science, University of Ghana, Legon, Ghana

⁶Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK

⁷Ghana Health Service, Accra, Ghana

Correspondence to: Prof María-Gloria Basáñez, Department of Infectious Disease Epidemiology, Imperial College London, St Mary's campus, Norfolk Place, London, W2 1PG, UK, Office: +44 (0)20 7594 3295, m.basanez@imperial.ac.uk

Alternative contact: Dr Mike Osei-Atweneboana, Department of Environmental Biology and Health, Council for Scientific and Industrial Research, Water Research Institute, P.O. Box M 32, Accra, Ghana, Office: +233 (0)21 777651, ext. 1002, osei-atweneboana@yahoo.co.uk

© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

†Contributed equally to this work

Summary of key points: The first 3 years of biannual ivermectin distribution in Ghana have substantially reduced *Onchocerca volvulus* infection levels in 10 sentinel communities, but longitudinal analysis indicates that some communities are still consistently responding sub-optimally to treatment, with implications for onchocerciasis elimination.

Abstract

Background. Several African countries have adopted a biannual ivermectin distribution strategy in some foci to control and eliminate onchocerciasis. In 2010, the Ghana Health Service started biannual distribution to combat transmission hotspots and sub-optimal responses to treatment. We assessed the epidemiological impact of the first 3 years of this strategy and quantified responses to ivermectin over two consecutive rounds of treatment in 10 sentinel communities.

Methods. We evaluated *Onchocerca volvulus* microfilarial intensity and prevalence in those aged ≥ 20 years before the first, second and fifth (or sixth) biannual treatment rounds using skin snip data from 956 participants. We used longitudinal regression modelling to estimate rates of microfilarial repopulation of the skin in a cohort of 217 participants who were followed-up over the first two rounds of biannual treatment.

Results. Biannual treatment has had a positive impact, with substantial reductions in infection intensity after 4 or 5 rounds in most communities. We identified three communities—all having been previously recognised as responding sub-optimally to ivermectin—with statistically significantly high microfilarial repopulation rates. We did not find any clear association between microfilarial repopulation rate and the number of years of prior intervention, coverage, or the community level of infection.

Conclusions. The strategy of biannual ivermectin treatment in Ghana has reduced *O. volvulus* microfilarial intensity and prevalence, but sub-optimal responses to treatment remain evident in a number of previously and consistently implicated communities. Whether increasing the frequency of treatment will be sufficient to meet the World Health Organization's 2020 elimination goals remains uncertain.

In 1987, soon after ivermectin became licensed for human use [1], and following the first community trials [2], Ghana became one of the first countries to introduce mass treatment to control onchocerciasis (River Blindness). Ivermectin kills *Onchocerca volvulus* microfilariae (the larval progeny of adult worms that are transmissible to *Simulium* blackfly vectors) and temporarily sterilizes female worms such that numbers of microfilariae remain suppressed for at least three months following treatment [3]. Subsequently, females regain fertility and microfilariae repopulate the skin. Hence, ivermectin can only control onchocerciasis-associated disease—caused by immunopathological responses to chronic infection of the skin and ocular tissue by microfilariae [4]—when given at regular intervals. Infection can be eliminated if microfilariae are suppressed long enough to ensure that transmission is interrupted for at least 10 years, the average lifespan of adult worms [5]. Mass treatments with ivermectin have successfully eliminated onchocerciasis from foci in Mali and Senegal [6] (with annual or biannual distribution), Nigeria [7], Mexico [8], Colombia [9], Ecuador [10] and northern Venezuela [11]. (The strategy in Latin America has been mostly biannual treatment.) National programmes in Ethiopia and Uganda, among others, have adopted biannual distribution in some foci to accelerate progress towards elimination [12-14].

Despite years of ivermectin treatment in Ghana, and vector control in its savannah habitats, onchocerciasis still affects thousands of communities within 66 districts [15], and approximately 3.2 million people remain at risk of infection [16]. The resilience of onchocerciasis is probably partly due to poor responses to ivermectin in several Ghanaian communities [17, 18], raising fears of decreased ivermectin efficacy. In a community of normally responding individuals, microfilariae are expected to

reach about 10% of their pre-treatment numbers 6 months after treatment, and about 20% 1 year after treatment [3, 17]. In sub-optimally responding communities, microfilarial repopulation rates 6 months after treatment have been observed at over 50% [19]. Some of these communities are those that have been treated with most rounds of ivermectin [20].

In 2010, in response to the persistence of onchocerciasis in Ghana, the Neglected Tropical Diseases Programme (NTDP) of the Ghana Health Service (GHS) adopted a biannual treatment strategy in 44 out of 77 endemic communities [21]. Here, we report microfilarial loads and prevalence in 10 NTDP sentinel communities—some previously identified as responding sub-optimally to ivermectin—before and after 4 (or 5) rounds of biannual treatment. We evaluate responses to ivermectin by estimating rates of microfilarial repopulation in cohorts of individuals followed-up at 3 and 6 months after treatment, comparing skin repopulation rates with community endemicity, therapeutic coverage and number of years of prior ivermectin treatment. We discuss our results in the contexts of historical epidemiological data collected from these communities during annual ivermectin distribution and the World Health Organization (WHO)'s goals to eliminate onchocerciasis [22].

Methods

Ethical approval

Ethical approval was obtained from the ethics review committees of the Noguchi Memorial Institute for Medical Research, Ghana [NMIMR-IRB CPN 032110-11], the Ghana Health Service [GHS ERC 04_3_11], and Imperial College London Research and Ethics Committee [ICREC_11_2_4].

Study site

The study was conducted in 10 onchocerciasis endemic communities within savannah regions of Ghana (Figure 1). The communities were selected from some of the endemic areas where concerns on ivermectin efficacy have been previously reported [19]. By the time of this investigation, study communities had received between 14 and 23 rounds of annual ivermectin treatment.

Study design

The 10 selected communities had been scheduled to receive mass biannual treatments with ivermectin from July 2010. We used the inclusion/exclusion criteria for selecting communities described in [19], including communities previously identified as responding sub-optimally to ivermectin [17, 18, 20]. We recruited adults aged ≥ 20 years, randomly selected from different households. The number of eligible participants represented about 50–70% of the total population within the 10 studied communities. Those who were included represented about 10–40% of the total population and, of the total eligible population, approximately 70% in small communities (such as Asubende, with a population of 87) and roughly 20% in larger communities (such as New Longoro and Wiae with, respectively, populations of 1,650 and 1,611). The objectives and schedules of the study were explained to every individual, and those who agreed to participate signed a consent form.

Figure 2 illustrates the study design and times of treatment with ivermectin (150 μ g/kg, directly observed) using an example timeline of six trial participants. Skin snips of 956 consenting participants were taken in July 2010 just before the first round of biannual ivermectin treatment. All 956 participants were skin snipped six months later, in January 2011, just before the second biannual treatment round. A total of 217 (22.7%) of these participants (Table 1), who were positive for microfilariae in July 2010 (e.g. participants 1–5 in Figure 2), formed a cohort for evaluating rates of skin microfilarial repopulation. Within this cohort, the 186 participants (Table 1) positive for microfilariae in January 2011 (e.g. participants 1–4 in Figure 2) were skin snipped in April 2011 and in July 2011, just before the third round of biannual ivermectin treatment (some participants were lost to follow-up, e.g. participants 3 and 4 in Figure 2). Three further rounds of ivermectin treatment were distributed approximately every six months, in April 2012, December 2012 and June 2013, as part of GHS NTDP activities. Before the final round of treatment, in June 2013, a final round of skin snipping of consenting participants (e.g. participants 1, 3, 4 and 6 in Figure 2) was repeated.

Techniques used to count microfilariae in skin snip biopsies are described in Supplementary Methods, *Parasitological methods*.

Community Microfilarial Load and Community Microfilarial Prevalence

We calculated Community Microfilarial Load (CMFL) [23] and Community Microfilarial Prevalence (CMFP) as our primary and secondary indicators of community infection levels in the adult (aged ≥ 20 years) population. These were calculated before the first round of biannual treatment in July 2010, before the second round, in January 2011, and before the 5th or 6th round in March 2013 or June 2013 (the schedules of each community differed slightly). CMFL and CMFP calculations are given in Supplementary Methods, *Community microfilarial load and community microfilarial prevalence*.

Community treatment history and coverage

We obtained data on the community treatment coverage (Supplementary Figure A) at all treatment rounds from the NTDP to facilitate interpretation of CMFL and CMFP throughout the study. Coverage was calculated using treatment and census data provided by the community ivermectin distributors to the NTDP. It refers to the therapeutic coverage in the total population. Historical records of coverage were also obtained from the GHS NTDP.

Microfilarial repopulation

We constructed log-linear marginal regression models [24] to describe the average number of microfilariae per skin snip (mf/ss) in the longitudinal cohort of 217 individuals (Table 1, Figure 2), adjusting for community, participant age and sex. We constructed two models to analyse the data (Table 2). Both permit repopulation rates to vary among communities but the first (Model 1A and 1B, Table 2) permits repopulation rates to vary between the two consecutive repopulation periods, while the second (Model 2, Table 2) estimates a single community-specific repopulation rate, combining information from both repopulation periods. Mathematical details are given in Supplementary Methods, *Marginal regression models*.

We compared microfilarial repopulation rates graphically and by identifying communities with statistically significantly different estimates compared with a reference community (Takumdo). We also explored graphically how repopulation rates correlated with prior number of years of ivermectin treatment, therapeutic coverage, and CMFL just before the start of biannual treatment.

Results

Trends in community infection

Figure 3 presents community-specific CMFLs calculated in July 2010, January 2011 and March (or June) 2013 (CMFLPs are presented in Supplementary Figure B). We include the dates when each round of biannual treatment was distributed and the population coverage. The impact of the first round of biannual treatment appears somewhat greater than that in subsequent rounds, as demonstrated by the slightly faster decline in CMFL between round 1 (July 2010), and round 2 (January 2011), compared with that between round 2 and the final assessment of infection levels in March (or June) 2013 (compare the gradients of the dotted lines in Figure 3). This trend is most apparent in Asubende, Jagbenbendo, New Longoro, Senyase and Wiae, and least pronounced in Agborlekame 1 and Takumdo. In Ohiampe, community infection levels were greater in June 2013 than in July 2010, despite 4 rounds of treatment (one round was missed in the first quarter of 2013).

Trends in microfilarial repopulation

Figure 4 presents the observed and model-fitted (from Model 1A, Table 2) mean number of mf/ss by sampling date and community in the reference demographic stratum of males in the (20,40] age group. We also include the model-predicted mean number of microfilariae per skin snip (mf/ss) in October 2010 (3 months after the first round of biannual treatment), indicating the likely microfilarial dynamics during the first six-month repopulation period. In general, mean numbers of mf/ss per stratum are lower after the second repopulation period than after the first; microfilariae cannot repopulate completely in six months before further suppression by another treatment round. Mean numbers of mf/ss per stratum in January 2011, six months after the start of biannual treatment, are quite high compared with those in July 2010 (one expects microfilariae to reach about 10% of their pre-treatment population level after six months [3]).

Microfilarial repopulation rates

We define the rate of microfilarial repopulation as the mean number of mf/ss expressed as a percentage of the mean immediately before the preceding treatment with ivermectin. This captures

how quickly microfilariae reappear in the skin between consecutive treatment rounds. Figure 5 provides *standardized six-month* repopulation rates, adjusted by the differing exact durations between sampling times (calculated from Model 1B in Table 2; non-standardized repopulation rates are depicted in Supplementary Figure C). These estimates confirm that microfilarial repopulation rates are generally quite high, typically approximately 50% during the first period of repopulation, and similar, albeit somewhat more variable after the second repopulation period. The repopulation rates in Asubende and Kyingakrom after the second round of treatment are statistically significantly higher than in the reference community of Takumdo.

Figure 6 presents the single relative rates of repopulation by community (estimated using Model 2, Table 2) compared to Takumdo. Over both repopulation periods, rates of repopulation are statistically significantly ($P < 0.05$) higher in Asubende, Kyingarom and New Longoro compared with Takumdo. Graphically, we find no obvious association between the relative rate of microfilarial repopulation and: (i) the number of annual treatments with ivermectin before the start of the study (Figure 6B), (ii) the CMFL before the first biannual treatment (Figure 6C), or (iii) the average coverage of ivermectin distribution during the cohort component of the study (Figure 6D, see Supplementary Figure A for disaggregated coverage data).

Discussion

Onchocerciasis in Ghana remains resilient to the long-standing and large-scale (antivectorial and antiparasitic) interventions implemented over the past 40 years [25]. Despite having been earmarked for elimination as a public health problem by 2015 [16], there exist persistent hotspots of transmission [19, 26, 27] and reports of *O. volvulus* microfilariae repopulating the skin of patients faster than expected following treatment with ivermectin [19,20], a phenomenon also documented in Cameroon [28]. In 2010, and responding to this challenge, the GHS implemented biannual mass ivermectin treatment in many endemic communities [21]. We report on trends in community-wide infection with *O. volvulus* in 10 Ghanaian communities over the first 3 years of this biannual strategy and evaluate rates of microfilarial repopulation in cohorts of participants over the first two rounds of treatment.

The last systematic evaluation of community infection levels in many of the studied communities was in 2004/2005, after 10–18 annual mass ivermectin treatments [19] (Supplementary Table A and Supplementary Table B). Comparing these values with infection levels in July 2010 shows that the intervening 6 years of annual ivermectin mass treatment have reduced CMFLs generally by at least 50%. Infection levels were further reduced by March or June 2013, after 3 years of biannual treatment. Reductions in CMFL were > 36% in most communities and the CMFP was statistically significantly less than 10% in 5 out of 10 communities (Supplementary Table A and Supplementary Table B). Hence, the biannual strategy has had a positive impact.

Whether residual infection levels constitute a public health problem would be best evaluated by measuring levels of onchocerciasis-associated morbidity. However, it is hard to envisage declaring the problem eliminated in communities where microfilarial prevalence is > 10%, or > 20% as in Jagbenbendo. Moreover, whether biannual treatments will ultimately be sufficient to eliminate *infection* will depend on local transmission and programmatic conditions, particularly on the intensity of blackfly biting [25, 26] and the sustainability of high levels of treatment coverage and adherence [29, 30]. One of the objectives of the NTD Modelling Consortium (www.ntdmodelling.org) is to determine what intervention strategies will be necessary to eliminate infection in the timelines set out by the WHO Roadmap on NTDs [22].

The six-month rates of repopulation estimated here are broadly around 50% and are high compared with the expected 10% from parasite populations predominantly naïve to ivermectin [3]. They are also higher than those estimated from some of the same communities in 2005, which were typically < 30% (Supplementary Table C). Some of this discrepancy is probably because the 10% value (and the previous estimates from these communities) were based on *geometric means* which are not strictly comparable with the model-derived repopulation rates presented here (which correspond to arithmetic means). Further, the sampling scheme employed in this study (and previously in the same communities [19]) followed up only participants who were positive for microfilariae at recruitment. This ensures that only people infected with *O. volvulus* are repeatedly skin snipped, increasing the efficiency of sampling when the prevalence of infection is low. Unfortunately, this necessary protocol

potentially introduces sampling biases because the sensitivity of skin snipping declines with decreasing infection intensity [31]. Hence, participants with less intense infections are more likely to be erroneously deemed uninfected and not followed up. This will probably upwardly bias repopulation rates because more intensely infected people will have more microfilariae after a period of repopulation than those with less intense infections.

Notwithstanding these cautions, the three communities with the highest repopulation rates over the two repopulation periods (Asubende, Kyingakrom, New Longoro) have been previously implicated as responding sub-optimally to ivermectin [19, 20, 27]. A mechanistic cause underlying these observations cannot be determined from the statistical analysis presented here. However, previous suggestions that faster rates of skin repopulation by microfilariae might result from a sudden increase in new infections between treatment rounds—perhaps due to programmatic deficiencies in coverage and compliance [32, 33]—are difficult to reconcile with the generally high levels of therapeutic coverage observed throughout (Figures 6D) and before (Supplementary Figure A) the study. It is more likely that transmission has been declining since the onset of biannual ivermectin treatment in July 2010, as evidenced by the generally falling CMFL (Figure 3), although noteworthy is the resilience of community infection levels to biannual distribution in Kyingakrom (Supplementary Table A and Supplementary Table B).

Work is ongoing to evaluate the genotype of adult parasites extracted from some of the participants of this study. Previous analyses comparing allele frequencies among adult female *O. volvulus* infecting people in multiply treated and ivermectin-naïve populations in Ghana and Cameroon identified selection of P-glycoprotein and β -tubulin genes, both associated with resistance to ivermectin in helminth infections of livestock [34, 35]. Moreover, a genetic analysis of the entire region of the β -tubulin gene extracted from worms infecting people from Kyingakrom—a consistently implicated sub-optimally responding community—has identified statistically significantly higher frequencies of 6 single nucleotide polymorphisms [36]. How the phenotypic response of individual worms relates to these genetic changes remains incompletely understood. Worms collected from sub-optimally responding communities have been associated with higher fertility than worms from putatively

normally responding communities [36], possibly indicative of a faster resumption of fertility following exposure to ivermectin [28]. However, results elsewhere suggest that selection driven by exposure to ivermectin is associated with a pleiotropic fitness cost of decreased fertility [35], so perhaps putatively resistant worms can resume production of microfilariae more rapidly than their susceptible counterparts, but ultimately have less reproductive potential.

Our conclusions on microfilarial repopulation rates are based on average, community estimates, adjusted for individual (host) characteristics such as age and sex. This is consistent with the inferential basis of previous, more descriptive, analyses of data from some of the same communities studied here [19, 27]. Yet, particularly for these well-studied and relatively small communities, many of the same individuals have probably repeatedly participated in the epidemiological studies undertaken over the last 15 years. Hence, future analyses should focus on estimating drug responses at the individual level [37, 38]. It is more plausible that certain individuals, rather than entire communities, are consistently responding poorly to ivermectin (and influencing the community-wide response). Poor individual responses to treatment might be caused by host-related factors or—given the long life span of adult *O. volvulus*—by drug-tolerant parasites.

The biannual ivermectin treatment strategy is markedly reducing *O. volvulus* infection levels in Ghana. However, despite high and sustained therapeutic coverage, sub-optimal responses to ivermectin persist in previously implicated communities. Whether this is caused by drug-tolerant or resistant parasites, or by host-related factors remains unclear. Analyses are yet to be performed to test the hypothesis that community-level sub-optimal responses are driven by a minority of consistently poorly responding individuals (or their worms) and to identify underlying mechanisms. The EPIONCHO and ONCHOSIM mathematical transmission models are being used to assess the feasibility of meeting the WHO elimination goals with annual or biannual ivermectin treatment [29, 30, 38, 39], and in future they will be used to establish which settings may require alternative or complementary strategies (such as test-and-treat macrofilaricidal doxycycline therapy [40] and/or focal vector control). Such modelling projections cover a wide range of epidemiological and

programmatic contexts, but should also accommodate the possibility that ivermectin may not be as universally efficacious as hoped.

Acknowledgements

We would like to acknowledge the contributions from the research team involved in the field work of this study, ivermectin distributors, participants, members of the various communities and the Ghana Health Service's posts within the local districts for their cooperation during the long-term follow-ups. Our gratitude also goes to the NTDP in Accra, Ghana especially to Mr Odame Asiedu and Mr Paul Yikpotey for providing us with the long-term coverage data for this study. The cooperation from the participating institutions is also acknowledged for providing the laboratory space and logistics towards the progress of this research, especially CSIR-WRI and Imperial College London.

Funding

This work was supported by a Royal Society–Leverhulme Trust (Capacity Building) Africa Award [to MYO-A and MGB]. MW and MGB acknowledge funding from the Wellcome Trust [grant no. 092677/Z/10/Z] and from the NTD Modelling Consortium by the Bill and Melinda Gates Foundation in partnership with the Task Force for Global Health. MW and MGB also acknowledge that this investigation received financial support from the UNICEF/UNDP/World Bank WHO Special Programme for Research and Training in Tropical Disease (TDR) [grant no. 2015/540029-0].

Disclaimer

The views, opinions, assumptions or any other information set out in this article are solely those of the authors. The funders had no role in writing the manuscript or in the decision to submit it for publication.

Potential conflicts of interest

The authors declare that they have no conflict of interests.

References

1. Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. *Proc Jpn Acad Ser B Phys Biol Sci.* **2011**; 87:13–28.
2. Alley ES, Plaisier AP, Boatman BA, Dadzie KY, Remme J, Zerbo G, et al. The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. *Trans R Soc Trop Med Hyg* **1994**; 88:581–4.
3. Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on *Onchocerca volvulus*: a systematic review and meta-analysis. *Lancet Infect Dis* **2008**; 8:310–22.
4. Brattig NW. Pathogenesis and host responses in human onchocerciasis: impact of *Onchocerca filariae* and *Wolbachia* endobacteria. *Microbes Infect* **2004**; 6:113–28.
5. Plaisier AP, van Oortmarssen GJ, Remme J, Habbema JDF. The reproductive lifespan of *Onchocerca volvulus* in West African savanna. *Acta Trop* **1991**; 48:271–84.
6. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. *PLoS Negl Trop Dis* **2012**; 6:1371.
7. Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. *Parasit Vectors* **2012**; 5:28.
8. Rodríguez-Pérez MA, Fernández-Santos NA, Orozco-Algarra ME, Rodríguez-Atanacio JA, Domínguez-Vázquez A, Rodríguez-Morales KB, et al. Elimination of onchocerciasis from Mexico. *PLoS Negl Trop Dis* **2015**; 9:e0003922.

9. West S, Munoz B, Sommer A. River blindness eliminated in Colombia. *Ophthalmic Epidemiol* **2013**; 20:258–9.
10. Lovato R, Guevara A, Guderian R, Proaño R, Unnasch T, Criollo H, et al. Interruption of infection transmission in the onchocerciasis focus of Ecuador leading to the cessation of ivermectin distribution. *PLoS Negl Trop Dis* **2014**; 8:e2821.
11. Convit J, Schuler H, Borges R, Olivero V, Domínguez-Vázquez A, Frontado H, et al. Interruption of *Onchocerca volvulus* transmission in Northern Venezuela. *Parasit Vectors* **2013**; 6:289.
12. Katarwa M, Richards F. Twice-yearly ivermectin for onchocerciasis: the time is now. *Lancet Infect Dis* **2014**; 14:373-374.
13. Katarwa M, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, et al. Transmission of *Onchocerca volvulus* by *Simulium naevei* in Mount Elgon focus of Eastern Uganda has been interrupted **2014**; 90:1159-1166.
14. African Programme for Onchocerciasis Control (APOC). Report of the thirty-eighth session of the technical consultative committee. Available at: http://www.who.int/apoc/about/structure/tcc/tcc38_final_report_130814.pdf. Accessed 4 March 2016.
15. Ministry of Health Ghana Health Service. Two-year strategic plan for integrated neglected tropical diseases control in Ghana. 2007. Available at: <http://www.moh-ghana.org/UploadFiles/Publications/Plan%20for%20Pro-Poor%20Diseases120506091943.pdf>. Accessed 4 March 2016.
16. Taylor MJ, Awadzi K, Basáñez MG, Biritwum N, Boakye D, Boatman B, et al. Onchocerciasis control: Vision for the future from a Ghanaian perspective. *Parasit Vectors* **2009**; 2:7.

17. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. *Ann Trop Med Parasitol* **2004**; 98:231–49.
18. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. *Ann Trop Med Parasitol* **2004**; 98:359–70.
19. Osei-Atweneboana MY, Eng JKL, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of *Onchocerca volvulus* infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. *Lancet* **2007**; 369:2021–9.
20. Churcher TS, Pion SDS, Osei-Atweneboana MY, Prichard RK, Awadzi K, Boussinesq M, et al. Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. *Proc Natl Acad Sci USA* **2009**; 106:16716–21.
21. Turner HC, Osei-Atweneboana MY, Walker M, Tettevi EJ, Churcher TS, Asiedu O, et al. The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study. *PLoS Negl Trop Dis* **2013**; 7:e2452.
22. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. Geneva: World Health Organization; 2012. Available at: http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf. Accessed 4 March 2016.
23. Remme J, Ba O, Dadzie KY, Karam M. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. *Bull World Health Organ* **1986**; 64:667–81.
24. Diggle P, Heagerty P, Liang KY, Zeger SL. *Analysis of Longitudinal Data*. 2nd ed. Oxford: Oxford University Press; **2013**.

25. Lamberton PHL, Cheke RA, Winskill P, Tirados I, Walker M, Osei-Atweneboana MY, et al. Onchocerciasis transmission in Ghana: persistence under different control strategies and the role of the simuliid vectors. *PLoS Negl Trop Dis* **2015**; 9:e0003688.
26. Lamberton PHL, Cheke RA, Walker M, Winskill P, Osei-Atweneboana MY, Tirados I, et al. Onchocerciasis transmission in Ghana: biting and parous rates of host-seeking sibling species of the *Simulium damnosum* complex. *Parasit Vectors* **2014**; 7:511.
27. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK. Phenotypic evidence of emerging ivermectin resistance in *Onchocerca volvulus*. *PLoS Negl Trop Dis* **2011**; 5:e998.
28. Pion SDS, Nana-Djeunga HC, Kamgno J, Tendongfor N, Wanji S, Njiokou F, et al. Dynamics of *Onchocerca volvulus* microfilarial densities after ivermectin treatment in an ivermectin-naïve and multiply treated population from Cameroon. *PLoS Negl Trop Dis* **2013**; 7: e2084.
29. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG. Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. *PLoS Negl Trop Dis* **2013**; 7:e2169.
30. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, et al. Reaching the London Declaration on Neglected Tropical Diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. *Clin Infect Dis* **2014**; 59:923–32.
31. Taylor HR, Munoz B, Keyvan-Larijani E, Greene BM. Reliability of detection of microfilariae in skin snips in the diagnosis of onchocerciasis. *Am J Trop Med Hyg* **1989**; 41:467–71.
32. Cupp E, Richards F, Lammie P, Eberhard M. Efficacy of ivermectin against *Onchocerca volvulus* in Ghana. *Lancet* **2007**; 370:1123.

33. Remme JHF, Amazigo U, Engels D, Barryson A, Yameogo L. Efficacy of ivermectin against *Onchocerca volvulus* in Ghana. *Lancet* **2007**; 370:1123–4.
34. Eng JK, Prichard PK. A comparison of genetic polymorphism in populations of *Onchocerca volvulus* from untreated- and ivermectin-treated patients. *Mol Biochem Parasitol* **2006**; 142:193–202.
35. Bourguinat C, Pion SDS, Kamgno J, Gardon J, Duke BOL, Boussinesq M, et al. Genetic selection of low fertile *Onchocerca volvulus* by ivermectin treatment. *PLoS Negl Trop Dis* **2007**; 1:e72.
36. Osei-Atweneboana MY, Boakye DA, Awadzi K, Gyapong JO, Prichard RK. Genotypic analysis of β -tubulin in *Onchocerca volvulus* from communities and individuals showing poor parasitological response to ivermectin treatment. *Int J Parasitol Drugs Drug Resist* **2012**; 2:20–8.
37. Walker M, Churcher TS, Basáñez MG. Models for measuring anthelmintic drug efficacy for parasitologists. *Trends Parasitol* **2014**; 30:528–37.
38. Coffeng LE, Stolk WA, Hoerauf A, Habbema D, Bakker R, Hopkins AD, et al. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment. *PLoS One* **2014**; 9:e115886.
39. Stolk WA, Walker M, Coffeng LE, Basáñez MG, de Vlas SJ. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. *Parasit Vectors* **2015**; 8:552.
40. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. *Clin Infect Dis* **2015**; 60: 1199–1207.

Figure Legends

Figure 1. Map of Ghana indicating administrative regions and locations of study communities.

Figure 2. Schematic timeline and illustrative history of six trial participants of the study used to evaluate community trends in infection and rates of microfilarial repopulation following the onset of a biannual treatment strategy in 10 Ghanaian communities. Participants 1-6 represent 6 of the 956 consenting individuals from whom skin snips were taken in July 2010 just before the first round of biannual ivermectin treatment and the again, six months later, in January 2011, just before the second round of biannual ivermectin treatment. Participants 1-5 were positive for microfilariae in July 2010 and hence were included in the cohort of 217 individuals for evaluating rates of skin microfilarial repopulation. Participants 1-4 represent 4 of the 186 individuals who were microfilariae positive in January 2011, with participants 1 and 2 successfully followed up and skin snipped in April 2011 and again in July 2011, just before the third round of biannual ivermectin treatment. Participants 1, 3, 4 and 6 represent 4 of the original 956 participants who agreed to be skin snipped for a final time in June 2013, just before the final round of treatments delivered by the Ghana Health Service Neglected Tropical Disease Programme. The months given on the timeline are the modal months of treatment activity among the 10 communities, but there is significant variation in the months and exact dates, especially for the biannual treatments given after July 2011 (see Figure 3 for exact dates).

Figure 3. Trends in community microfilarial loads in 10 Ghanaian communities from the onset of a biannual ivermectin treatment strategy. Community Microfilarial Load (CMFL) is defined as the geometric mean number of microfilariae per skin snip in people aged 20 years and above. Coloured arrows indicate dates when mass treatment with ivermectin was distributed, by either the authors or the Community Ivermectin Distributors. Ivermectin was administered directly after skin snipping on dates when microfilarial load was assessed. Data on the community therapeutic coverage of ivermectin were collated by the Ghana Health Service. Note that the six scheduled rounds of biannual ivermectin treatment were successfully delivered to only 5 (Asubende; Baaya; Kyingakrom; New Longoro and Senyase) out of the 10 communities; the others communities (Agborlekame 1;

Jagbenbendo; Ohiampe; Takumdo, and Wiae) achieved five rounds of biannual treatment. Vertical lines indicate 95% confidence intervals calculated using a non-parametric bootstrap technique (see Supplementary Methods, Community Microfilaria Load and Community Microfilarial Prevalence). Dotted lines join estimated values and are for presentation purposes only. Triangles indicate times of ivermectin treatment and numbers above triangles indicate the therapeutic coverage in the whole community.

Figure 4. Trends in mean numbers of microfilariae (mf per skin snip, ss) per participant in 10 Ghanaian communities from the onset of a biannual ivermectin treatment strategy. Data points represent observed mean microfilarial loads, by community, in the reference strata of males within the (20,40] age group. The solid vertical lines are corresponding 95% bootstrap confidence intervals. Triangles indicate when ivermectin was administered to the study participants. Solid lines join fitted estimated values—and in the case of October 2010, predicted values—from the marginal regression model which includes additive stratum adjustments for age group and sex, and interactive adjustments between sampling date and community (Model 1A in Table 2). Dotted lines join the corresponding 95% confidence bounds calculated using robust sandwich estimators of coefficient standard errors (see Supplementary Methods, Marginal regression models). The predicted values in October 2010 are provided to assist the reader to envisage the likely dynamics in mean numbers of mf/ss between the first and second sampling date. These predictions were generated from the marginal regression model that treats the time since the preceding ivermectin treatment as a continuous variable (Model 2 in Table 2) and assumes that (hypothetical) microfilarial sampling took place midway between the July 2010 and January 2011 sampling times. Note that data from Baaya are not shown because only 1 participant was microfilaria-positive and followed up in this community (Table 1), leading to very large associated estimates of uncertainty.

Figure 5. Six-month microfilarial repopulation rates in 10 Ghanaian communities from the onset of a biannual ivermectin treatment strategy. Filled and open data points represent, respectively estimated mean microfilarial loads six months after the first or second round of ivermectin treatment expressed as a percentage of the microfilarial load estimated just before the preceding round of ivermectin

treatment. These estimates are derived from Model 1B (Table 2) which adjusts for the variable follow-up times among communities, permitting estimation of directly comparable standardized six-month rates of repopulation. Note that the six-month microfilarial repopulation rate from Baaya is not shown because only 1 participant was microfilaria-positive and followed up in this community (Table 1), leading to very large associated estimates of uncertainty. Vertical lines indicate 95% confidence bounds, calculated using robust sandwich estimators of coefficient standard errors (see Supplementary Methods, Marginal regression models). Stars indicate P values comparing the rate of repopulation with the reference village of Takumdo: *** $P < 0.001$; ** $P < 0.01$.

Figure 6. Relative six-month microfilarial repopulation rates in 10 Ghanaian communities over the first two rounds of a biannual ivermectin treatment strategy. Data points represent the estimated relative (multiplicative) six-month microfilarial repopulation in each community compared with Takumdo. Six-month repopulation rates are defined as mean microfilarial loads six months after a round of ivermectin treatment expressed as a percentage of the microfilarial load estimated just before the preceding treatment round. Estimates are derived from Model 2 (Table 2) that treats time since the preceding ivermectin treatment as a continuous covariate interacting with the indicator covariate for community. The six-month microfilarial repopulation rate from Baaya is not shown because only 1 participant was microfilaria-positive (Table 1), leading to very large associated estimates of uncertainty. (A) Estimates are plotted side-by-side for the different communities. (B) Estimates are plotted against the number of years of ivermectin treatment preceding the biannual strategy. (C) Estimates are plotted against CMFL preceding the first biannual ivermectin treatment (D) Estimates are plotted against the mean coverage of ivermectin distribution for the years 2010 and 2011 corresponding to the component of the study when the longitudinal cohort of participants was followed up over two consecutive rounds of biannual treatment (see also Supplementary Figure A for disaggregated coverage data from 2005 to 2013). Vertical lines are 95% confidence bounds, calculated using robust sandwich estimators of coefficient standard errors (see Supplementary Methods, Marginal regression models). Solid horizontal lines in panel C indicate 95% confidence bounds associated with the estimated CMFL, calculated using a numerical bootstrap resampling

method (see Supplementary Methods, Community Microfilarial Load and Community Microfilarial Prevalence). Stars indicate P values comparing with the reference village of Takumdo: * $P < 0.05$.

Accepted Manuscript

Tables

Table 1. Longitudinal cohorts of participants in 10 Ghanaian communities who were followed up and skin snipped over the first two rounds of biannual treatment with ivermectin


Community	Month and year (months since preceding round of treatment)			
	July 2010 (0) ^a	January 2011 (6) ^b	April 2011 (3)	July 2011 (6)
Agborlekame 1	63	27	23	20
Asubende	34	9	8	9
Baaya	129	1	1	1
Jagbenbendo	107	50	47	46
Kyingakrom	82	14	12	12
New Longoro	126	17	13	15
Ohiampe	85	5	5	4
Senyase	64	8	6	7
Takumdo	108	50	48	44
Wiae	158	26	23	24
Total	956	217	186	182

^a Only participants positive for microfilariae were followed up in January 2011; ^b only participants positive for microfilariae followed up in April 2011 and July 2011.


Table 2. Key features of the log-linear marginal regression models used to describe the observed microfilarial counts in the longitudinal cohort

Type	Variant	Key features
Model 1	A & B	<ul style="list-style-type: none"> • Response/outcome variable defined by individual microfilarial counts • Modelled mean number of microfilariae per participant adjusted for the covariates age group (0,20], (20,40], (40,60] and (60,82], sex and community • Microfilarial repopulation rates permitted to vary among communities and between repopulation periods by including sampling time as a categorical covariate interacting with community
	B	<ul style="list-style-type: none"> • Microfilarial repopulation rates adjusted by exact number of days since preceding round of ivermectin treatment yielding standardized repopulation rates (e.g. six-month repopulation rates)
Model 2	–	<ul style="list-style-type: none"> • Response/outcome variable defined by individual microfilarial counts • Modelled mean number of microfilariae per participant adjusted for the covariates age group (0,20], (20,40], (40,60] and (60,82], sex and community • A single microfilarial repopulation rate estimated for each community, combining information from both repopulation periods, by including sampling time as a continuous covariate—defined as days since preceding ivermectin treatment—interacting with community • Additive, community-wide adjustments for potentially different repopulation rates between two repopulation periods


STUDY AREAS IN THE SELECTED DISTRICTS




Accepted Manuscript



Accepted Manuscript




ACCEP







Accepted

Accepted Manuscript



107



Accepted